Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of hepatitis C virus (HCV) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and prevalence of HCV for…

Clarivate Epidemiology’s coverage of  hepatitis c virus (HCV) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…

Chemotherapy and hormonal therapy have been the mainstay treatments of advanced endometrial carcinoma, but treatment is becoming more directed, as a result of tumor analysis. Immune checkpoint…

Of the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China’…

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment…

Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy, even as novel agents like Orgovyx (Myovant) enter the treatment algorithm. Zytiga (…

The treatment landscape for squamous cell carcinoma of the head and neck (SCCHN) witnessed a major change in 2019 with the approval of Merck & Co.’s Keytruda for untreated recurrent or metastatic…

Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current lipid-modifying therapies include statins, ezetimibe, fibrates, omega-3 fatty acid compounds…

Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates…

The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next decade. The well-established TNF-α inhibitors (e…

Clarivate Epidemiology’s coverage of acute kidney injury comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France,…

Because of the dearth of targeted treatments in China, patients with relapsed/refractory (R/R) NHL, multiple myeloma, or ALL continue to be prescribed salvage chemotherapy in later lines of…